Consolidated Portfolio Review Corp Ishares Tr Genomics Immunology Transaction History

Consolidated Portfolio Review Corp

$632 Billion
Q4 2024

A detailed history of Consolidated Portfolio Review Corp transactions in Ishares Tr Genomics Immunology stock. As of the latest transaction made, Consolidated Portfolio Review Corp holds 12,816 shares of IDNA stock, worth $287,206. This represents 0.05% of its overall portfolio holdings.

Number of Shares

12,816

Previous 14,366 10.79%

Holding current value

$287,206

Previous $354 Million 17.98%

% of portfolio

0.05%

Previous 0.08%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 27, 2025	SELL	$22.38 - $25.53 $34,689 - $39,571	-1,550 Reduced 10.79%	12,816 $290 Million
Q3 2024 Oct 23, 2024	SELL	$22.86 - $25.49 $2,560 - $2,854	-112 Reduced 0.77%	14,366 $354 Million
Q2 2024 Jul 31, 2024	BUY	$21.71 - $24.69 $9,009 - $10,246	415 Added 2.95%	14,478 $335 Million
Q1 2024 Apr 30, 2024	BUY	$22.28 - $25.2 $18,002 - $20,361	808 Added 6.1%	14,063 $339 Million
Q4 2023 Jan 29, 2024	BUY	$17.37 - $23.3 $42,817 - $57,434	2,465 Added 22.85%	13,255 $305 Million
Q3 2023 Nov 13, 2023	SELL	$20.35 - $24.44 $52,340 - $62,859	-2,572 Reduced 19.25%	10,790 $220 Million
Q2 2023 Aug 14, 2023	SELL	$23.05 - $25.1 $43,702 - $47,589	-1,896 Reduced 12.43%	13,362 $312 Million
Q1 2023 May 11, 2023	BUY	$22.48 - $27.9 $342,999 - $425,698	15,258 New	15,258 $355 Million

Others Institutions Holding IDNA

# of Institutions

Shares Held

1.75M

Call Options Held

Put Options Held

View Full List

About ISHARES TR GENOMICS IMMUNOLOGY

Ticker IDNA
Sector ETFs
Industry ETFs

More about IDNA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Consolidated Portfolio Review Corp, based on Form 13F filings with the SEC.

News

Stay updated on Consolidated Portfolio Review Corp with notifications on news.

Account

Consolidated Portfolio Review Corp Ishares Tr Genomics Immunology Transaction History